Moreover, small-molecule GS inhibitors (GSis) can increase surface BCMA levels by reducing the cleavage of BCMA from the membrane, subsequently improving MM cell recognition by anti-BCMA ADCs. The gene discussed is TNFRSF17; the disease is Miyoshi myopathy.